Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer

[1]  F. Ghiringhelli,et al.  Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer , 2011, Cancer Immunology, Immunotherapy.

[2]  K. Taskén,et al.  Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells. , 2011, Cellular signalling.

[3]  M. Resnick,et al.  Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors , 2010, Journal of surgical oncology.

[4]  A. Nowak,et al.  Harnessing the immune response to treat cancer , 2010, Oncogene.

[5]  Shuji Ogino,et al.  Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.

[6]  R. Lambert,et al.  The dimensions of the CRC problem. , 2010, Best practice & research. Clinical gastroenterology.

[7]  G. Kouraklis,et al.  Role of surgery in colorectal liver metastases: too early or too late? , 2010, World journal of gastroenterology.

[8]  L. Terracciano,et al.  High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.

[9]  M. Koch,et al.  Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. , 2009, The Journal of clinical investigation.

[10]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Roncarolo,et al.  Is FOXP3 a bona fide marker for human regulatory T cells? , 2008, European journal of immunology.

[12]  K. Taskén,et al.  Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. , 2008, Critical reviews in oncogenesis.

[13]  E. Aandahl,et al.  Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner , 2008, Cancer Immunology, Immunotherapy.

[14]  M. Thun,et al.  A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. , 2007, Journal of the National Cancer Institute.

[15]  S. Fox,et al.  Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. , 2007, Cancer immunity.

[16]  J. Spratt,et al.  Treatment of hepatic metastases from colorectal carcinoma , 1998, Journal of Gastrointestinal Surgery.

[17]  Geraint T. Williams,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer , 2006, PloS one.

[18]  N. Rothman,et al.  Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[20]  E. Aandahl,et al.  FOXP3+CD4+CD25+ Adaptive Regulatory T Cells Express Cyclooxygenase-2 and Suppress Effector T Cells by a Prostaglandin E2-Dependent Mechanism1 , 2006, The Journal of Immunology.

[21]  K. Arihiro,et al.  Tumor-driven evolution of immunosuppressive networks during malignant progression. , 2006, Cancer research.

[22]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[23]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[24]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[25]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[26]  M. Kay Washington,et al.  Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma Cells* , 2001, The Journal of Biological Chemistry.

[27]  R. Miller,et al.  Increased tight junctional permeability is associated with the development of colon cancer. , 1999, Carcinogenesis.

[28]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[29]  J. Morrow,et al.  Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.

[30]  J. Morrow,et al.  Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.

[31]  R. DuBois,et al.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.